Business Standard

Tuesday, December 24, 2024 | 10:50 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Moderna says patent ruling not to affect Covid-19 vaccine development

Moderna shares were up slightly in extended trading, while Arbutus shares closed down 20% on Friday

moderna
Premium

Moderna said the court's ruling relates to actions it took in response to "longstanding aggressive posture".

Reuters
Moderna Inc said on Friday its formula used in developing a Covid-19 vaccine was not covered under patents owned by Arbutus Biopharma.

An administrative court run by the US Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a US patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine.

Moderna said the court's ruling relates to actions it took in response to "longstanding aggressive posture" taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its Covid-19 vaccine candidate.

ALSO READ: 

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in